Search

Harrihar A Pershadsingh

from Bakersfield, CA
Age ~78
Get Report
Also known as:
Hap Pershadsingh, Ha Pershadsingh, Pershadsingh Hap, R H
Phone and address:
404 Windsor Park Dr, Bakersfield, CA 93311
(661) 664-9640
Related to:
Nikolaos S Miller, 48Bdt D Pershadsingh, 80H J PershadsinghDeborah L Pershadsingh, 72Rajendra B Pershadsingh, 70Bob PershadBishun Pershadsingh, 78Valentino R Remesar, 80
Connected to:
David L Pershall, 52Gary W Pershall, 53Jonathan R Pershall, 50Linda L Pershall, 76Peter S Pershan, 89Rasul Pershay, 39Andrew Pershe, 33Steven S Pershern, 48Anna Pershing, 43Anne P Pershing, 79

Harrihar Pershadsingh Phones & Addresses

  • 404 Windsor Park Dr, Bakersfield, CA 93311 (661) 664-9640
  • 1114 Seaward St, San Luis Obispo, CA 93405
  • Woodland Hills, CA
  • Montara, CA

Work

Company: Kern Medical Center Address: 1830 Flower Street, Bakersfield, CA 93305

Education

School / High School: University Of Missouri--Columbia School Of Medicine 1984

Languages

English • Spanish

Awards

Healthgrades Honor Roll

Ranks

Certificate: Family Practice, 1995

Specialities

Family Medicine

Professional Records

Medicine Doctors

Harrihar Pershadsingh Photo 1

Dr. Harrihar A Pershadsingh, Bakersfield CA - MD (Doctor of Medicine)

View page
Specialties:
Family Medicine
Address:
2201 Mount Vernon Ave Suite 211, Bakersfield, CA 93306
(661) 872-7000 (Phone), (661) 872-0499 (Fax)
Certifications:
Family Practice, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Spanish
Hospitals:
2201 Mount Vernon Ave Suite 211, Bakersfield, CA 93306

Kern Medical Center
1830 Flower Street, Bakersfield, CA 93305
Education:
Medical School
University Of Missouri--Columbia School Of Medicine
Graduated: 1984
Medical School
Barnes Jewish Hospital
Graduated: 1985
Medical School
Barnes Jewish Hospital
Graduated: 1986
Medical School
Kern Med Center
Graduated: 1993
Harrihar Pershadsingh Photo 2

Harrihar Ajodhya Pershadsingh, Bakersfield CA

View page
Specialties:
Family Physician
Address:
2201 Mount Vernon Ave, Bakersfield, CA 93306
1111 Columbus St, Bakersfield, CA 93305
Education:
University of Missouri, School of Medicine (Columbia) - Doctor of Medicine
Kern Medical Center - Residency - Family Medicine
Barnes-Jewish Hospital - Residency - Clinical Pathology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Harrihar A. Pershadsingh
President
BETHESDA PHARMACEUTICALS, INC
Noncommercial Research Organization
333 Main St #4A, San Francisco, CA 94105
404 Windsor Park Dr, Bakersfield, CA 93311
Harrihar Pershadsingh
Doctor Of Medicine
Perez Jose A Jr MD
Offices of Physicians (except Mental Health Specialists)
2201 Mt Vernon Ave STE 211, Bakersfield, CA 93306
(661) 872-7000
Harrihar Ajodhya Pershadsingh
Harrihar Pershadsingh MD,PHD
Family Doctor
2201 Mt Vernon Ave, Bakersfield, CA 93306
(661) 872-7000

Publications

Us Patents

1,2-Dithiolane Derivatives

View page
US Patent:
6353011, Mar 5, 2002
Filed:
Mar 7, 2000
Appl. No.:
09/520208
Inventors:
Harrihar A. Pershadsingh - Bakersfield CA
Mitchell A. Avery - Oxford MS
Assignee:
University of Mississippi - University MI
International Classification:
C07D41712
US Classification:
514369, 548183, 549 39, 560 9, 562426
Abstract:
This invention provides new thiazolindinedione derivatives and new arylacetic acid derivatives. These compounds are useful for the treatment of cardiovascular diseases, certain endocrine diseases, certain inflammatory diseases, certain neoplastic (malignant) and non-malignant proliferative diseases, certain neuro-psychiatric disorders, certain viral diseases, and diseases associated with these viral infections as discussed herein.

Dithiolane Derivatives

View page
US Patent:
6369098, Apr 9, 2002
Filed:
Oct 4, 2000
Appl. No.:
09/684738
Inventors:
Harrihar A. Pershadsingh - Bakersfield CA
Mitchell A. Avery - Oxford MS
Assignee:
Bethesda Pharmaceuticals, Inc. - Bakersfield CA
International Classification:
A61K 31385
US Classification:
514440, 549 32, 549 35, 549 39
Abstract:
The present invention describes methods for synthesizing novel dithiolane derivatives, ligands with high affinity for the nuclear hormone receptors, peroxisome proliferator-activated receptor- (PPAR) and/or PPAR. Methods for using these compounds in the treatment of endocrine, skin, cardiovascular, immunological, neurological, neuropsychiatric, neoplastic and chronic viral diseases of various organs, including the eye are described. Methods of treating proliferative and inflammatory diseases, degenerative diseases, and age-related dysregulations, caused by an hereditary (genetic) condition or an environmental insult are also provided. In addition, methods are provided for treating conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, a PPAR agonist, and a second agent selected from the following: a PPAR ligand, or an RXR ligand (rexinoid), or a PPAR/RXR ligand, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.

Antioxidants

View page
US Patent:
6664287, Dec 16, 2003
Filed:
Mar 14, 2001
Appl. No.:
09/809518
Inventors:
Mitchell Allen Avery - Oxford MS
Harrihar A. Pershadsingh - Bakersfield CA
Assignee:
Bethesda Pharmaceuticals, Inc. - Bakersfield CA
International Classification:
A61K 31385
US Classification:
514436, 549 20, 549 21, 549 22
Abstract:
This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and/or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e. g. diabetes mellitus, atherosclerosis, Alzheimers disease and chronic viral diseases) and non-pathological (e. g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin. The compositions described in this invention increase cellular viability of epidermal cells, promote cytoprotection, and decrease the production of inflammatory mediators such as inflammatory cytokines in these cells.

Ppar Ligands That Do Not Cause Fluid Retention, Edema Or Congestive Heart Failure

View page
US Patent:
7232828, Jun 19, 2007
Filed:
Jul 24, 2003
Appl. No.:
10/627372
Inventors:
Harrihar A. Pershadsingh - Bakersfield CA, US
Assignee:
Bethesda Pharmaceuticals, Inc. - Mill Valley CA
International Classification:
A61K 31/519
US Classification:
5142591, 5412581
Abstract:
Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes. Compounds are provided that antagonize or block the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs), can be used to treat or prevent diseases known to be treatable or preventable by PPAR activators and were not previously recognized to be therapeutic targets for angiotensin II receptor antagonists.

Design And Synthesis Of Optimized Ligands For Ppar

View page
US Patent:
7339065, Mar 4, 2008
Filed:
Jul 21, 2004
Appl. No.:
10/565492
Inventors:
Mitchell A. Avery - Oxford MS, US
Harrihar A. Pershadsingh - Bakersfield CA, US
Assignee:
Bethesda Pharmaceuticals, Inc. - Bakerfield CA
The University of Mississippi - University MS
International Classification:
A61K 31/426
C07D 277/34
US Classification:
548183, 514369
Abstract:
This invention provides new chemical entities useful for treating a variety of clinical disorders including those that are influenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5adamantan-2-yl-pentanoic acid {2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.

Ppar Ligands That Do Not Cause Fluid Retention, Edema Or Congestive Heart Failure

View page
US Patent:
7812046, Oct 12, 2010
Filed:
Apr 27, 2007
Appl. No.:
11/796453
Inventors:
Harrihar A. Pershadsingh - Bakersfield CA, US
Assignee:
Bethesda Pharmaceuticals, Inc. - Bakersfield CA
International Classification:
A01N 43/50
A61K 31/415
US Classification:
514385
Abstract:
Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes. Compounds are provided that antagonize or block the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs), can be used to treat or prevent diseases known to be treatable or preventable by PPAR activators and were not previously recognized to be therapeutic targets for angiotensin II receptor antagonists.

Compositions Comprising Novel Ppar Ligands And Anti-Hyperlipemic Agents

View page
US Patent:
7867991, Jan 11, 2011
Filed:
Nov 10, 2006
Appl. No.:
11/595550
Inventors:
Harrihar A. Pershadsingh - Bakersfield CA, US
Assignee:
Bethesda Pharmaceuticals, Inc. - Bakersfield CA
International Classification:
A01N 43/64
A61K 31/41
US Classification:
514183, 514381
Abstract:
Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating or preventing conditions comprising hypertension and dyslipidemia, comprising antihyperlipemic agents which lower triglycerides and inhibit cholesterol synthesis such as statins, and compounds that antagonize or block the angiotensin II type 1 (AT1) receptor, activate PPARs and lower triglycerides or elevate blood HDL-cholesterol such as sartans.

Methods Of Preventing Allograft Rejection

View page
US Patent:
20020019344, Feb 14, 2002
Filed:
Feb 26, 2001
Appl. No.:
09/795043
Inventors:
Harrihar Pershadsingh - Bakersfield CA, US
International Classification:
A61K038/13
A61K031/66
A61K031/573
A61K031/522
A61K031/4741
US Classification:
514/009000, 514/291000, 514/369000, 514/179000, 514/261000, 514/105000, 514/532000, 514/534000
Abstract:
Methods of promoting allograft survival, by attenuating or preventing allograft rejection, and treating or ameliorating the post-transplantation syndrome complex associated with allograft rejection and immunosuppressive pharmacotherapy used to prevent allograft rejection, are described. These methods comprise administering to an human or animal in need of treatment an effective amount of an insulin-sensitizing compound or and pharmaceutically acceptable salts and solvates thereof, administered alone or in combination with other immunosuppressive drugs.
Control profile
Harrihar A Pershadsingh from Bakersfield, CA, age ~78 Get Report